ARCAGY-GINECO   Report issue

For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Paris France (1993)

Organization Overview

First Clinical Trial
2001
NCT00231075
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

ARCAGY/ GINECO GROUP | GINECO | GINECO - Centre François Baclesse | GINECO GROUP

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Adenocarcinoma, Clear Cell (Phase 2)

Adenomyoepithelioma (Phase 2)

Biliary Tract Neoplasms (Phase 2)

Breast Neoplasms (Phase 3)

Carcinoma (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 4)

Carcinosarcoma (Phase 3)

Endometrial Neoplasms (Phase 2)

Fallopian Tube Neoplasms (Phase 3)

Genital Diseases, Female (Phase 3)

Hypersensitivity (Phase 3)

Mixed Tumor, Mullerian (Phase 3)

Neoplasm Metastasis (Phase 2)

Neoplasms (Phase 3)

Neurotoxicity Syndromes (Phase 2)

Ovarian Diseases (Phase 3)

Ovarian Neoplasms (Phase 4)

Pancreatic Neoplasms (Phase 2)

Peritoneal Neoplasms (Phase 3)

Recurrence (Phase 3)

Sex Cord-Gonadal Stromal Tumors (Phase 2)

Uterine Cervical Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 45
  • # of Trial APIs: 39